VHLH抗原，腦視網(wǎng)膜血管瘤G7蛋白抗原（逢希伯-林道氏?。?/h1>

發(fā)布時(shí)間：2024/11/20點(diǎn)擊次數(shù)：115

Recombinant human VHLH   

pVHL; pVHL; G7 protein; Elongin binding protein; HRCA 1; HRCA1; Protein G7; pVHL; RCA 1; RCA1; VHL 1; VHL; VHL_HUMAN; VHL1; VHLH; Von Hippel Lindau disease tumor suppressor; von Hippel Lindau syndrome; von Hippel Lindau tumor suppressor; Von Hippel-Lindau disease tumor suppressor.    

濃度：1mg/ ml

來源：Recombinant Human

純度：≥95% SDS-PAGE

表達(dá)系統(tǒng)：Escherichia coli

標(biāo)簽：His tag

蛋白長度：Full length protein

內(nèi)毒素水平：<1.000 Eu/µg

純化方法：HPLC

應(yīng)用：SDS-PAGE，Western blot，ELISA

Biological activity,immunology research

保存：-20℃

保質(zhì)期：1年

Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases.

產(chǎn)品名稱：Rabbit Anti-VHLH  antibody

Rabbit Anti-VHLH  

別名：pVHL; pVHL; G7 protein; Elongin binding protein; HRCA 1; HRCA1; Protein G7; pVHL; RCA 1; RCA1; VHL 1; VHL; VHL_HUMAN; VHL1; VHLH; Von Hippel Lindau disease tumor suppressor; von Hippel Lindau syndrome; von Hippel Lindau tumor suppressor; Von Hippel-Lindau disease tumor suppressor.        

來源：Rabbit

克隆類型：Polyclonal

濃度：1mg/ml

亞型：IgG

應(yīng)用： WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500

反應(yīng):Human

免疫原：KLH conjugated synthetic peptide derived from human VHLH

保存：-20℃
保質(zhì)期：1年

 

單克隆抗體

產(chǎn)品名稱：Anti-VHLH antibody

Mouse Anti-VHLH 

別名：pVHL; pVHL; G7 protein; Elongin binding protein; HRCA 1; HRCA1; Protein G7; pVHL; RCA 1; RCA1; VHL 1; VHL; VHL_HUMAN; VHL1; VHLH; Von Hippel Lindau disease tumor suppressor; von Hippel Lindau syndrome; von Hippel Lindau tumor suppressor; Von Hippel-Lindau disease tumor suppressor.     

來源：Mouse

克隆類型：Monoclonal

濃度：1mg/ml

亞型：IgG

應(yīng)用： WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500

反應(yīng): Human

免疫原：KLH conjugated synthetic peptide derived from human VHLH

保存：-20℃
保質(zhì)期：1年

Involved in the ubiquitination and subsequent proteasomal degradation via the von Hippel-Lindau ubiquitination complex. Seems to act as target recruitment subunit in the E3 ubiquitin ligase complex and recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions. Involved in transcriptional repression through interaction with HIF1A, HIF1AN and histone deacetylases.

文件下載